In an open, dose-finding study, a 100% cure rate was observed in patients suffering from uncomplicated gonococcal urethritis who were treated with a single oral dose of either 1.2 g (n = 10), 0.8 g (n = 11), or 0.4 g (n = 10) of cefetamet pivoxil. The MICs of cefetamet for all gonococcal strains ranged from 0.001 to 0.12 ,ug/ml, and the MIC for 90% of the strains tested was 0.008 Lg/ml. Cefetamet pivoxil was ineffective against Chlamydia trachomatis in 3 of 31 patients. Side effects were minor.
The incidence of plasmid-and chromosome-mediated drug resistance of Neisseria gonorrhoeae to treatment with penicillin or tetracycline has become a serious worldwide problem (1, 6, 9, 13, 14) . The development of an alternative anitmicrobial therapy is therefore justified. Intramuscular treatment of patients with broad-spectrum cephalosporins has proved to be highly effective in the eradication of penicillinase-producing N. gonorrhoeae (PPNG) and nonpenicillinase-producing N. gonorrhoeae (non-PPNG) and is therefore the therapy of first choice in our clinic (8, 12) .
Cefetamet pivoxil (Ro 15-8075) is a new oral cephalosporin. When given orally with food, approximately 50% of this prodrug ester is absorbed in the intestinal tract and is hydrolyzed into the active free acid cefetamet (2, 3 (10) .
All gonococcal strains were tested for the production of P-lactamase by using the chromogenic cephalosporin (nitrocefin) test (4) . MICs of the free acid cefetamet and penicillin G for N. gonorrhoeae were determined by the agar dilution technique with twofold dilutions between 128 and 0.001 jxg/ml (9) .
A total of 41 men were enrolled in this study. Of these, 31 patients were evaluable; the other 10 were not evaluable because they did not return for follow-ups. Their test results were in accordance with their histories of treated late latent syphilis. N. gonorrhoeae was isolated only from the urethra of each patient before treatment. At follow-ups, this bacterium was absent in all evaluable patients treated with 1.2, 0.8, or 0.4 g of cefetamet pivoxil.
C. trachomatis was isolated from 2 of the 31 evaluable patients before and from 3 (one in each dose group) of the 31 patients after therapy. Cefetamet pivoxil appeared to be ineffective against this microorganism. In this study, patients with concomitant chlamydial infections were additionally treated with 100 mg of doxycycline twice a day for 7 days after the second follow-up.
The MICs of the free acid cefetamet and penicillin G for N. gonorrhoeae strains were determined for a total of 41 patients ( Table 1 ). The MICs of cefetamet for all strains ranged from 0.001 to 0.12 ,ug/ml and were comparable to those found by an earlier study (investigational brochure, Hoffmann-La Roche). One patient who was treated with 1.2 g of cefetamet pivoxil had a slightly elevated total bilirubin level 7 days after therapy. This adverse effect was probably not caused by cefetamet pivoxil because of the pharmacokinetics of this drug and because laboratory findings 2 days after treatment were normal. One patient who was treated with 0.4 g of cefetamet pivoxil complained of an itch in the scrotum before therapy which increased in intensity after therapy.
Since N. gonorrhoeae was isolated only from the urethra in our study population, the efficacy of cefetamet pivoxil against oropharyngeal or rectal gonorrhea could not be evaluated.
The brief follow-up period precludes any conclusion concerning postgonococcal urethritis in our study. Postgonococcal urethritis would appear 2 to 3 weeks after treatment of gonorrhea (5) .
Our preliminary findings may indicate that cefetamet pivoxil is a safe and effective drug for the treatment of uncomplicated gonococcal urethritis caused by PPNG and non-PPNG. The efficacy and the safety of cefetamet pivoxil against N. gonorrhoeae compare well with those of other oral cephalosporins (7, 11) . In this study, a single oral dose of 0.4 g of cefetamet pivoxil was sufficient to cure uncomplicated gonococcal urethritis. However, further investigation with a larger group of patients should be conducted to confirm the beneficial effect of this drug in the treatment of uncomplicated gonococcal urethritis.
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